• Commenced strategic review to assess pathways for future US medicinal market entry
• Leveraging EU-GMP accredited production platform and proprietary genetics portfolio
• Established EU-GMP capability provides structural advantage over many Canadian and US peers

ECS Botanics Holdings Ltd (ASX:ECS), a leading medicinal cannabis company, has commenced a strategic review to assess potential pathways for future entry into the United States medicinal cannabis market. The review reflects increasing global regulatory convergence in medicinal cannabis and is designed to ensure ECS is strategically and operationally positioned to act should compliant US market access pathways emerge. ECS operates as a fully EU-GMP accredited cultivator and manufacturer, providing a structural advantage relative to many Canadian and US producers that do not operate under full EU-GMP frameworks. This capability enables faster regulatory alignment, lower compliance risk, and improved access to tightly regulated export markets. ECS has already secured California-origin genetics and operates scalable, export-ready infrastructure, providing asset-backed, execution-ready optionality should compliant US market pathways emerge. The Company continues to benefit from increased enforcement by the German regulator BfArM around GMP integrity and supplier compliance, which favors fully compliant suppliers and supports ECS's ongoing access to Europe's largest medicinal cannabis market. ECS is fully funded and maintains a robust balance sheet, providing execution-ready flexibility to respond decisively to regulatory developments while maintaining strict capital discipline.

No decision has been made to enter the US market at this stage, and any future action would be contingent on regulatory clarity, compliance requirements and disciplined capital allocation.